

# Supplementary Figures for “CoxFormer enables spatial omics inference with multimodal generative modeling”

Yiyang Yang<sup>1,3†</sup>, Xu Liao<sup>1†</sup>, Haoyu Zhang<sup>1†</sup>, Yida Wu<sup>1</sup>, Xiaobo Sun<sup>2</sup>, Yao Wang<sup>3\*</sup>, Tianshu Yu<sup>1\*</sup>, and Jin Liu<sup>1\*</sup>

<sup>1</sup>School of Data Science, The Chinese University of Hong Kong-Shenzhen, Shenzhen, China,

<sup>2</sup>Department of Human Genetics, Emory University School of Medicine, Atlanta, USA.

<sup>3</sup>School of Management, Xi’an Jiaotong University, Xi’an, China,

<sup>†</sup>Equal contributions.

\*Corresponding author. Email: yao.s.wang@gmail.com, yutianshu@cuhk.edu.cn, liujinlab@cuhk.edu.cn








**a****b****c****d**

Figure S1: **Gene Ontology (GO) enrichment analysis highlights major functional modules encoded by CoxFormer gene embeddings.** Shown here are representative functional categories recovered from the embedding manifold, where each panel pairs a gene cluster in the low-dimensional projection (left; representative genes annotated) with its top enriched GO terms (right; bars indicate  $-\log_{10}$  adjusted  $P$  values). **(a)** Blood-vessel and endothelial programs. **(b)** Interferon and antiviral immune response. **(c)** Cilium assembly and movement. **(d)** Epidermis and keratinocyte differentiation.





Figure S2: **Additional functional modules identified from the CoxFormer embedding manifold.** Shown here are representative functional categories recovered from the embedding manifold, where each panel pairs a gene cluster in the low-dimensional projection (left; representative genes annotated) with its top enriched GO terms (right; bars indicate  $-\log_{10}$  adjusted  $P$  values). **(a)** Extracellular-matrix organization and collagen fibril organization. **(b)** Neutrophil activation and cytokine-mediated inflammatory signaling. **(c)** Transcriptional regulation and RNA polymerase-associated processes.

**a**

**Distinguishes between bivalent and Lys4-only-methylated genes (whole genome)**



**b**

**Distinguishes between dosage-sensitive and dosage-insensitive transcription factors**





Figure S3: **Detailed per-task results for gene-level binary classification benchmarks (I)**. Results are reported for two classifiers (logistic regression and support vector machine) and five complementary evaluation metrics (AUC, Accuracy, F1, Precision, Recall), together with an aggregated overall score (rightmost column). Bubble size denotes the normalized score (higher is better) and bubble color encodes the ranking within each metric (lighter indicates better performance). **(a)** Distinguishes between bivalent and Lys4-only-methylated genes (whole genome). **(b)** Distinguishes between dosage-sensitive and dosage-insensitive transcription factors.

**a**

**Differentiates between long-range and short-range transcription factors (TFs)**



**b**

**Identifies differences between bivalent and non-methylated genes**





Figure S4: **Detailed per-task results for additional gene-level binary classification benchmarks (II)**. Results are reported for two classifiers (logistic regression and support vector machine) and five complementary evaluation metrics (AUC, Accuracy, F1, Precision, Recall), together with an aggregated overall score (rightmost column). Bubble size denotes the normalized score (higher is better) and bubble color encodes the ranking within each metric (lighter indicates better performance). **(a)** Differentiates between long-range and short-range transcription factors (TFs). **(b)** Identifies differences between bivalent and non-methylated genes.

**a**

**Human CD34+ Bone Marrow (BM)**



**b**

**Breast Cancer FFPE (BC)**





Figure S5: **Detailed per-dataset results for cell-type clustering and classification benchmarks (I)**. Results are reported for four scRNA-seq datasets and summarized into an aggregated overall cell-task score (rightmost column; higher indicates better performance; Methods). Two complementary evaluations are included: unsupervised clustering (ARI, NMI, AMI) and supervised cell-type classification (AUC, Accuracy, F1, Precision, Recall). Bubble size denotes the normalized score (higher is better) and bubble color encodes the ranking within each metric (lighter indicates better performance). **(a)** Human CD34<sup>+</sup> Bone Marrow (BM). **(b)** Breast Cancer FFPE (BC).

**a**

**Diffuse Large B-cell Lymphoma FFPE (DLBL)**



**b**

**Lung Cancer FFPE (LC)**




Figure S6: **Detailed per-dataset results for additional cell-type clustering and classification benchmarks (II)**. Results are reported for four scRNA-seq datasets and summarized into an aggregated overall cell-task score (rightmost column; higher indicates better performance; Methods). Two complementary evaluations are included: unsupervised clustering (ARI, NMI, AMI) and supervised cell-type classification (AUC, Accuracy, F1, Precision, Recall). Bubble size denotes the normalized score (higher is better) and bubble color encodes the ranking within each metric (lighter indicates better performance). **(a)** Diffuse Large B-cell Lymphoma FFPE (DLBL). **(b)** Lung Cancer FFPE (LC).




Figure S7: **Detailed results for pseudo-panel gene prediction on six human breast cancer (HBC) Visium datasets.** We compare CoxFormer with scRNA-seq reference-based baselines across the aggregated set (ALL) and each individual dataset (HBC1-HBC6). Prediction quality is assessed by three complementary metrics: Pearson correlation coefficient (PCC), structural similarity index (SSIM), and root mean squared error (RMSE). Ablation variants (CoxFormer-Loc, CoxFormer-Img, CoxFormer-Learn) are included to quantify the contribution of different modalities; incorporating comprehensive spatial context yields the best overall performance.




Figure S8: **ATAC-derived gene activity score (GAS) prediction.** We compare CoxFormer with three ablated variants that isolate individual information sources: gene co-expression, gene correlation, and gene description. **(a)** Spatial GAS prediction for five representative genes (*SMIM27*, *BIN2*, *ASAH1*, *NPAS4*, *SMDT1*), showing that CoxFormer better matches the ground-truth spatial contrast and localization than individual-source variants. **(b)** Region-by-gene GAS heatmaps based on top differentially expressed genes (DEGs) between DG GCL and CA3 Pyr, where CoxFormer more faithfully preserves the underlying block-wise structure.




Figure S9: **Visual comparison of super-resolution gene maps between CoxFormer and iStar.** We visualize enhanced-resolution predictions for representative genes by comparing ground-truth, CoxFormer, and iStar. CoxFormer produces smoother and more spatially coherent expression patterns that better aligned with tissue structure, whereas iStar often yields fragmented and patchy maps.




Figure S10: **Zero-shot marker gene super-resolution prediction and multi-scale Xenium validation: extracellular-matrix-associated stromal programs.** Using the 56 genes unobserved in both sections, we evaluate CoxFormer in a stringent zero-shot regime and compare its subcellular-scale predictions with Xenium ground truth for representative marker genes that delineate distinct tissue compartments. Multi-scale visualizations are shown at four resolutions (4 $\times$ , 16 $\times$ , 64 $\times$ , and 256 $\times$ ), together with matched H&E context and the corresponding zoom-in locations on the whole-slide image (*LUM*, *COL6A3*).




Figure S11: **Zero-shot marker gene super-resolution prediction and multi-scale Xenium validation: epidermis/immune compartment markers.** Using the 56 genes unobserved in both sections, we evaluate CoxFormer in a stringent zero-shot regime and compare its subcellular-scale predictions with Xenium ground truth for representative marker genes that delineate distinct tissue compartments. Multi-scale visualizations are shown at four resolutions (4 $\times$ , 16 $\times$ , 64 $\times$ , and 256 $\times$ ), together with matched H&E context and the corresponding zoom-in locations on the whole-slide image (*CD3D*, *CLDN1*).




Figure S12: **Full-section zero-shot super-resolution predictions with Xenium ground truth.** In a stringent zero-shot setting where target genes are entirely absent from the measured panel, we visualize full-section predictions for representative unobserved genes by comparing Xenium ground truth with CoxFormer outputs.



Figure S13: **CCC analysis before and after transcriptome-wide imputation in Section B.** **(a)** Spatial NMF factors are visualized on Section B before imputation and after imputation by CoxFormer, illustrating clearer region-resolved programs after transcriptome-wide expansion. **(b)** Ligand-receptor dotplots are inferred from the original 280-gene panel (top), where CCC inference is underpowered and yields only four robust ligand-receptor pairs, versus the transcriptome-expanded data after CoxFormer imputation (bottom), where the inferred CCC landscape become substantially richer.




Figure S14: **Spatial patterns of ligand-receptor pairs identified from dotplot CCC analysis after transcriptome-wide imputation.** The spatial maps reveal region-aligned signaling programs across tissue compartments, including extracellular-matrix and adhesion interactions (e.g., *COL1A1*→*SDC1*, *THBS2*→*SDC1*, *FN1*→*SDC1*), epidermal junction programs with strong epidermis-associated specificity (e.g., *DSG1*→*DSC3* and *DSC2*→*DSG3*), and immune recognition signals enriched in the immune-infiltrated region (e.g., *SFTPD*→*LAIR1* and *SFTPD*→*SIRPA*).







Figure S15: **Example results of abnormal-region annotation on the untreated colorectal cancer (CRC) section.** We compare CoxFormer with representative reference-required baselines (SpaGE, SpaOTsc, Tangram, gimVI, Seurat, stPlus, novoSpaRc, and LIGER). **(a)** Quantitative performance on this section, reporting AUROC (left) and complementary classification metrics (Accuracy, F1, Recall, Precision). **(b)** Spatial segmentation results are overlaid on the tissue, comparing predicted abnormal regions from each method with the ground-truth annotation. **(c)** UMAP visualization of the predicted labels from panel (b), illustrating separation between abnormal and normal spots under different methods. **(d)** Representative housekeeping-gene expression patterns for ground-truth versus CoxFormer predictions.







Figure S16: **Example results of abnormal-region annotation on the therapy-perturbed colorectal cancer (CRC) section.** We compare CoxFormer with representative reference-required baselines (SpaGE, SpaOTsc, Tangram, gimVI, Seurat, stPlus, novoSpaRc, and LIGER). **(a)** Quantitative performance on this section, reporting AUROC (left) and complementary classification metrics (Accuracy, F1, Recall, Precision). **(b)** Spatial segmentation results are overlaid on the tissue, comparing predicted abnormal regions from each method with the ground-truth annotation. **(c)** UMAP visualization of the predicted labels from panel (b), illustrating separation between abnormal and normal spots under different methods. **(d)** Representative housekeeping-gene expression patterns for ground-truth versus CoxFormer predictions.







Figure S17: **Example results of abnormal-region annotation on the untreated liver metastasis (LM) section.** We compare CoxFormer with representative reference-required baselines (SpaGE, SpaOTsc, Tangram, gimVI, Seurat, stPlus, novoSpaRc, and LIGER). **(a)** Quantitative performance on this section, reporting AUROC (left) and complementary classification metrics (Accuracy, F1, Recall, Precision). **(b)** Spatial segmentation results are overlaid on the tissue, comparing predicted abnormal regions from each method with the ground-truth annotation. **(c)** UMAP visualization of the predicted labels from panel (b), illustrating separation between abnormal and normal spots under different methods. **(d)** Representative housekeeping-gene expression patterns for ground-truth versus CoxFormer predictions.







Figure S18: **Example results of abnormal-region annotation on the therapy-perturbed liver metastasis (LM) section.** We compare CoxFormer with representative reference-required baselines (SpaGE, SpaOTsc, Tangram, gimVI, Seurat, stPlus, novoSpaRc, and LIGER). **(a)** Quantitative performance on this section, reporting AUROC (left) and complementary classification metrics (Accuracy, F1, Recall, Precision). **(b)** Spatial segmentation results are overlaid on the tissue, comparing predicted abnormal regions from each method with the ground-truth annotation. **(c)** UMAP visualization of the predicted labels from panel (b), illustrating separation between abnormal and normal spots under different methods. **(d)** Representative housekeeping-gene expression patterns for ground-truth versus CoxFormer predictions.



Figure S19: **Differential expression patterns of top marker genes between CoxFormer-segmented normal and abnormal regions in colorectal cancer (CRC) sections.** For each CRC section, we visualize the expression of the top 200 differentially expressed genes (DEGs) identified between the normal and abnormal regions segmented by CoxFormer, highlighting coherent region-wise contrasts associated with pathological states. **(a)** Untreated CRC section. **(b)** Therapy-perturbed (PR) CRC section.



Figure S20: **Differential expression patterns of top marker genes between CoxFormer-segmented normal and abnormal regions in liver metastasis (LM) sections.** For each LM section, we visualize the expression of the top 200 differentially expressed genes (DEGs) identified between the normal and abnormal regions segmented by CoxFormer, highlighting coherent region-wise contrasts associated with pathological states. **(a)** Untreated LM section. **(b)** Therapy-perturbed (PR) LM section.



**a****b**

Figure S21: **Training Pipeline and Training Analysis.** **(a)** Coxformer predicts gene co-expression by learning node embeddings and edge representations on a gene correlation graph. Although training starts from the global graph, optimisation is performed on correlation-guided sampled subgraphs for efficiency. For each target node (or candidate gene pair), we construct a compact computational neighbourhood by sampling first-order neighbours that provide direct co-expression context and second-order neighbours that add higher-order relational evidence via shared correlation partners. Node embeddings are updated via neighbourhood aggregation, edge representations are constructed from pairs of updated node embeddings, and an edge-value regressor outputs predicted co-expression (edge) weights for sampled gene pairs, yielding a graph with updated (predicted) edge weights. **(b)** Training analysis and prediction performance: (left) prediction and ground-truth values across sampled indices, (middle) scatter plot of prediction vs. ground truth (with the diagonal indicating perfect prediction), and (right) training loss curve over epochs.